Chemomab Therapeutics discloses CFO compensation: $260K salary, 45% bonus, 102,860 ADS options at $1.70

Chemomab Therapeutics Ltd.

Annual base salary of $260,000 for new CFO Sigal Fattal, plus customary social benefits.
Yearly bonus potential of 45% of base salary, based on mutually agreed objectives subject to Compensation Committee approval.
Grant of options to purchase 102,860 American Depositary Shares at $1.70 per ADS, vesting over 4 years.
Options accelerate upon a change in control (CIC); exercise period extended to 12 months post-termination (except for Cause).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.